Your research is unique. We tailor your Optimer discovery strategy to match, delivering the highest chance of success and the best Optimer performance. Download this booklet to learn how: …

07/07/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today provides an update on recent…

Protein-protein interactions were once considered undruggable. Our tailored aptamer selection approach is proving this isn’t so. Targets such as transcription factors, immune checkpoints in oncology, infectious disease agents, and…

Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…

When developing an aptamer to a protein target it’s important to keep in mind how you want to use it as much as what you want to bind. When developing…

14/06/2023 Optimer binders have been successfully developed to a novel Alzheimer’s disease biomarker Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and…

23/05/2023 Aptamer Group, the developer of novel Optimer® binders to enable innovation in the life sciences industry, in partnership with Bioliquid Innovative Genetics and Anima Design of Spain, announce that they…

April 25th is DNA day. This day celebrates the completion of the Human Genome Project 20 years ago and the discovery of DNA’s double helix 70 years ago,…

Virus recognition has been driven to the forefront of molecular recognition research due to the COVID-19 pandemic. Development of highly sensitive recognition elements, both natural and synthetic is critical…

20/03/2023   Existing pipeline of IHC work including potential trials with Optimer®-Fc with two top 10 pharma companies Aptamer is currently working with one of the top three IHC company…